
05 Jun 2023
Tristel: FDA approval — a significant inflection point
This content is only available within our institutional offering.

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Tristel: FDA approval — a significant inflection point
Tristel Plc (TSTL:LON) | 360 0 0.0% | Mkt Cap: 171.9m
- Published:
05 Jun 2023 -
Author:
Paul Cuddon | Kane Slutzkin -
Pages:
4 -